Societe Generale Downgrades Fresenius Medical Care AG Co. to Hold (FMS) - sleekmoney Print

Fresenius Medical Care AG & Co. (NYSE:FMS) was downgraded by Societe Generale from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, reports.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 0.91% on Thursday, reaching $41.15. The company’s stock had a trading volume of 78,366 shares. The company has a market cap of $25.07 billion and a P/E ratio of 23.66. The stock’s 50 day moving average price is $42.19 and its 200 day moving average price is $41.48. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.42 by $0.02. During the same period in the prior year, the company posted $0.42 EPS. The business had revenue of $4.20 billion for the quarter, compared to analyst estimates of $4.13 billion. Fresenius Medical Care AG & Co.’s quarterly revenue was up 15.0% on a year-over-year basis. Equities research analysts forecast that Fresenius Medical Care AG & Co. will post $1.75 earnings per share for the current year.

Other research analysts also recently issued reports about the stock. Commerzbank AG downgraded Fresenius Medical Care AG & Co. to a “hold” rating in a report on Friday, May 29th. RBC Capital upped their price target on shares of Fresenius Medical Care AG & Co. from $35.00 to $40.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $41.10.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.image

The Fly On The Wall